Literature DB >> 28913813

Pharmacotherapy Pearls for Emergency Neurological Life Support.

Gretchen M Brophy1, Theresa Human2.   

Abstract

The appropriate use of medications during Emergency Neurological Life Support (ENLS) is essential to optimize patient care. Important considerations when choosing the appropriate agent include the patient's organ function and medication allergies, potential adverse drug effects, drug interactions and critical illness and aging pathophysiologic changes. Critical medications used during ENLS include hyperosmolar therapy, anticonvulsants, antithrombotics, anticoagulant reversal and hemostatic agents, anti-shivering agents, neuromuscular blockers, antihypertensive agents, sedatives, vasopressors and inotropes, and antimicrobials. This article focuses on the important pharmacokinetic and pharmacodynamics characteristics, advantages and disadvantages and clinical pearls of these therapies, providing practitioners with essential drug information to optimize pharmacotherapy in acutely ill neurocritical care patients.

Entities:  

Keywords:  Adverse drug event; Drug interaction; ENLS; Medication; Pharmacotherapy

Mesh:

Year:  2017        PMID: 28913813     DOI: 10.1007/s12028-017-0456-x

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  63 in total

1.  Vasopressor use and effect on blood pressure after severe adult traumatic brain injury.

Authors:  Pimwan Sookplung; Arunotai Siriussawakul; Amin Malakouti; Deepak Sharma; Jin Wang; Michael J Souter; Randall M Chesnut; Monica S Vavilala
Journal:  Neurocrit Care       Date:  2011-08       Impact factor: 3.210

2.  Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.

Authors:  Lewis B Morgenstern; J Claude Hemphill; Craig Anderson; Kyra Becker; Joseph P Broderick; E Sander Connolly; Steven M Greenberg; James N Huang; R Loch MacDonald; Steven R Messé; Pamela H Mitchell; Magdy Selim; Rafael J Tamargo
Journal:  Stroke       Date:  2010-07-22       Impact factor: 7.914

3.  Prothrombin complex concentrates used alone in urgent reversal of warfarin anticoagulation.

Authors:  H Tran; M Collecutt; S Whitehead; H H Salem
Journal:  Intern Med J       Date:  2011-04       Impact factor: 2.048

Review 4.  Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient.

Authors:  Michael J Murray; Heidi DeBlock; Brian Erstad; Anthony Gray; Judi Jacobi; Che Jordan; William McGee; Claire McManus; Maureen Meade; Sean Nix; Andrew Patterson; M Karen Sands; Richard Pino; Ann Tescher; Richard Arbour; Bram Rochwerg; Catherine Friederich Murray; Sangeeta Mehta
Journal:  Crit Care Med       Date:  2016-11       Impact factor: 7.598

Review 5.  Evidence supporting idarucizumab for the reversal of dabigatran.

Authors:  Charles V Pollack
Journal:  Am J Emerg Med       Date:  2016-09-28       Impact factor: 2.469

6.  Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.

Authors:  Stuart J Connolly; Truman J Milling; John W Eikelboom; C Michael Gibson; John T Curnutte; Alex Gold; Michele D Bronson; Genmin Lu; Pamela B Conley; Peter Verhamme; Jeannot Schmidt; Saskia Middeldorp; Alexander T Cohen; Jan Beyer-Westendorf; Pierre Albaladejo; Jose Lopez-Sendon; Shelly Goodman; Janet Leeds; Brian L Wiens; Deborah M Siegal; Elena Zotova; Brandi Meeks; Juliet Nakamya; W Ting Lim; Mark Crowther
Journal:  N Engl J Med       Date:  2016-08-30       Impact factor: 91.245

7.  An examination of aneurysm rerupture rates with epsilon aminocaproic acid.

Authors:  Albert J Schuette; Ferdinand K Hui; Nancy A Obuchowski; Raymond R Walkup; Charles M Cawley; Daniel L Barrow; Owen B Samuels
Journal:  Neurocrit Care       Date:  2013-08       Impact factor: 3.210

Review 8.  Vasopressors for shock.

Authors:  M Müllner; B Urbanek; C Havel; H Losert; F Waechter; G Gamper
Journal:  Cochrane Database Syst Rev       Date:  2004

9.  Predictors and clinical implications of shivering during therapeutic normothermia.

Authors:  Neeraj Badjatia; Robert G Kowalski; J Michael Schmidt; Marc E Voorhees; Jan Claassen; Noeleen D Ostapkovich; Mary Presciutti; E Sander Connolly; David Palestrant; Augusto Parra; Stephan A Mayer
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

10.  Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial.

Authors:  M Irem Baharoglu; Charlotte Cordonnier; Rustam Al-Shahi Salman; Koen de Gans; Maria M Koopman; Anneke Brand; Charles B Majoie; Ludo F Beenen; Henk A Marquering; Marinus Vermeulen; Paul J Nederkoorn; Rob J de Haan; Yvo B Roos
Journal:  Lancet       Date:  2016-05-10       Impact factor: 79.321

View more
  1 in total

Review 1.  Preliminary guideline- and pathophysiology-based protocols for neurocritical care.

Authors:  Yasuhiro Norisue; Yoshihisa Fujimoto; Kazuma Nakagawa
Journal:  J Intensive Care       Date:  2018-08-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.